ESR1 and breast carcinoma: As a new generation of FASN inhibitors has recently entered the clinic, our study suggests that targeting FASN could be therapeutically exploited for the clinico-molecular management of the poor prognosis luminal-B subtype of ER+ breast cancer patients.